micro-community-banner
 
  • Saved

November 25, 2024

Did you know? Palliative care isn’t just for end-of-life situations—it’s a vital support system that can be integrated early in the disease process. Combined with disease-modifying treatments, it helps improve quality of life, manage symptoms, and reduce suffering, ensuring patients receive comprehensive care throughout their journey.

Could earlier integration of palliative care revolutionize how we support patients with chronic and serious illnesses?

background

Could earlier integration of palliative care revolutionize how we support patients with chronic and serious illnesses?

Profile Image
  • Saved

November 25, 2024
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors - PubMed

First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39489747/

Oncogenic RET alteration is an important, tissue-agnostic therapeutic target across diverse cancers. We conducted a first-in-human phase 1 study on SY-5007, a potent and selective RET inhibitor, in patients with...

SY-5007, a selective RET inhibitor, demonstrated promising efficacy and tolerability in RET-altered solid tumors, with an overall response rate of 57.8% and a median progression-free survival of 21.1 months.

Profile Image
  • Saved

November 25, 2024
Advances in targeted therapy and biomarker research in thyroid cancer - PubMed

Advances in targeted therapy and biomarker research in thyroid cancer - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/38501105/

Driven by the intricacy of the illness and the need for individualized treatments, targeted therapy and biomarker research in thyroid cancer represent an important frontier in oncology. The variety of...

Targeted therapy and biomarker research in thyroid cancer offer personalized treatments, minimizing side effects. Understanding genetic changes enhances precision medicine, improving patient outcomes and inspiring advancements in other cancers.

Profile Image
  • Saved

November 19, 2024
RET alterations: actionable oncogenic drivers across multiple tumor types

Cancer treatment has advanced with the development of precision therapies targeting proto-oncogene alterations. One such proto-oncogene is RET, which encodes a receptor tyrosine kinase involved in embryonic development.

Activating RET alterations have been identified as oncogenic drivers in various tumor types. The ret proto-oncogene (RET) is activated by 2 main mechanisms, ie, sporadic or germline mutations that activate the kinase domain and chromosomal rearrangements that fuse the kinase domain with upstream gene fragments, thereby leading to constitutive activation.

RET mutations occur in more than 95% of germline medullary thyroid cancer cases and approximately 50% of sporadic cases. By contrast, RET fusions occur in papillary thyroid cancer, accounting for up to 40% of sporadic cases and appearing at a higher frequency after radioiodine exposure. RET fusions also occur in nearly 1% to 2% of NSCLC cases and are associated with a high risk of brain metastases. Other tumor types associated with RET fusions (incidence <1%) include pancreatic, colorectal, ovarian, and salivary gland cancers.

Selective RET inhibitors have been shown to provide deep and durable responses in patients with RET alterations. Tumor-agnostic RET inhibition lends support for universal screening of solid tumors for RET alterations, preferably via tissue-based, next-generation sequencing and can be used to detect RET mutations and fusions.

Which patients do you screen for RET alterations, and what is your preferred method of screening?

  • November 19, 2024
    I order solid and liquid NGS panel on all metastatic and locally advanced solid tumors . RET is one of the markers.
  • November 19, 2024
    I also do NGS panel testing in all metastatic patients and this includes RET alterations
  • November 19, 2024
    I try to get NGS that also detects RET fusions in all patients with non-small lung cancer Stage IB and above. I would also check in other disease typed refractory to initial lines of therapy.
  • November 19, 2024
    Yes. Standard NGS ON tissue and liquid NGS in this day and age to base treatment on NGS findings

    • t

    Source : https://too.pa

  • September 19, 2024
    Everyone gets NGS- typically tissue and blood if able. I agree with colleagues as stated.
  • September 19, 2024
    I do NGS testing on all metastatic pts, which include RET testing in the panel
  • September 19, 2024
    I order it in all metastatic patients. I prefer RET testing as part of NGS.
  • September 19, 2024
    I order RET testing for all patients with metastatic solid tumors (e.g. lung, breast, colon, etc, etc).
  • September 19, 2024
    I order it in all metastatic patients. I prefer RET testing as part of NGS.
  • September 19, 2024
    I order it in all metastatic patients. I prefer RET testing as part of NGS.
  • August 26, 2024
    All metastatic patients and I use ngs with dna and rna based testing. This could be done on tissue of plasma
  • August 23, 2024
    I order tissue and liquid NGS on all advanced pts looking for RET fusions/alteratons. Will repeat liquid NGS on progression as well.
  • August 23, 2024
    Currently it is standard in our oncology practice to send for tissue NGS testing and/or liquid NGS for any patient with advanced solid malignancy at time of diagnosis. RET mutations are quite rare in lung cancer patients though.
  • August 22, 2024
    as i mentioned earlier,NGS should be done in all pts with cancer. I do NGS in all drugs are available for both ret mutations and fusion
  • August 22, 2024
    We do order an NGS panel either at initial presentation with metastatic disease and in relapse. Both tissue (initial) and liquid (initial and subsequent). Hopefully this can catch RET mutations. RNA and DNA sequencing both preferred
  • August 22, 2024
    I tend to test all stage IV patients with tIssue NGS - which includes RET mutations and activations. If there is not tissue or enough tissue then we order liquid NGS. Any solid organ malignancy that has a RET Mutation would be eligible for targeted therapy.
  • August 21, 2024
    I think all patients should be screened for RET as any targeted therapy will be superior to standard chemotherapy. I use NGS
  • August 21, 2024
    I check all stage iv solid cancers RET testing along with other mutations on NGS that Dos DNAand RNA testing, prefer tissue biopsy
  • August 20, 2024
    I test all patients with metastatic disease and I use next gen universally
  • August 20, 2024
    We do order an NGS panel either at initial presentation with metastatic disease and in relapse. Both tissue and liquid. Hopefully this can catch RET mutations and then use therapy post SOC.
  • August 20, 2024
    I test all metastatic solid tumors with NGS DNA and RNA panel that includes RET, tissue if available and liquid if not. For nonmetastatic, RET inhibitors are not yet approved
  • August 20, 2024
    i agree with my colleagues
    I test all my metastatic cancers with NGS with both tissue and liquid biopsy simultaneously. I look for both ret mutation and fusion. Excellent options are available
  • August 20, 2024
    I typically order an ngs panel either at initial presentation with metastatic disease and in first relapse. the ngs panel includes whole exome and transcriptome panel, preferably on tissue +/- plasma based testing.
  • August 19, 2024
    I test all stage IV cancers and most locally advanced cancers with no local therapy options with NGS which includes RET mutations and fusions, now we are checking NGS before using neoadjuvant chemo-immunotherapy in early-stage Non small cell lung caners. I use the Next Gen Sequencing platform with both DNA and RNA sequencing as fusions are better detected on RNA sequencing.
Profile Image
  • Saved

November 18, 2024
Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001 - PubMed

Durability of Response With Selpercatinib in Patients With RET-Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001 - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/39094065/

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or...

LIBRETTO-001 study demonstrates durable, robust responses to selpercatinib in RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer, with high objective response rates and long-term progression-free survival.

Profile Image